| VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 23, 2012) - Sirona Biochem Corp. (TSX VENTURE:SBM)(PINKSHEETS:SRBCF)(FRANKFURT:ZSB), announced today its lead compound for the treatment of Type 2 diabetes was effective in lowering blood glucose levels in a well-established preclinical diabetic model. Sirona Biochem's compound, SBM-TFC-039, significantly and rapidly reduced the blood glucose level in obese diabetic rats (Zucker). In an acute dosing study, six hours after treatment, the blood gluco...continued SBM:CA SRBCF |
Thursday, February 23, 2012
Sirona Biochem Announces Preclinical Results of Diabetes Compound
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment